Clopidogrel TAD

clopidogrel

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Clopidogrel TAD. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Clopidogrel TAD.

For practical information about using Clopidogrel TAD, patients should read the package leaflet or contact their doctor or pharmacist.

What is Clopidogrel TAD and what is it used for?

Clopidogrel TAD is a medicine used to prevent problems caused by blood clots in adults who have:

  • recently had a myocardial infarction (heart attack). Clopidogrel TAD can be started between a few days and 35 days after the attack;
  • recently had an ischaemic stroke (stroke caused by failure of the blood supply to part of the brain). Clopidogrel TAD can be started between seven days and six months after the stroke;
  • peripheral arterial disease (problems with blood flow in the arteries);
  • a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots). Acute coronary syndrome is a group of heart problems that include heart attacks and unstable angina (a severe type of chest pain). Some of these patients may have had a stent (a short tube) placed in an artery to prevent it from closing up;
  • atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin. It is used in those patients who have at least one risk factor for vascular events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.

Clopidogrel TAD is a ‘generic medicine’. This means that Clopidogrel TAD is similar to a ‘reference medicine’ already authorised in the European Union (EU) called Plavix. 

Clopidogrel TAD contains the active substance clopidogrel.

How is Clopidogrel TAD used?

Clopidogrel TAD is available as tablets containing 75 mg clopidogrel. The standard dose is one 75-mg tablet once a day.

In acute coronary syndrome, treatment generally starts with a loading dose of four tablets. This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST segment elevation’ myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave’ myocardial infarction).

In acute coronary syndrome and atrial fibrillation, Clopidogrel TAD is used together with aspirin, the dose of which should not be higher than 100 mg.

Clopidogrel TAD can only be obtained with a prescription.

How does Clopidogrel TAD work?

The active substance in Clopidogrel TAD, clopidogrel, is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming. When the blood clots, this is due to special cells in the blood called platelets aggregating (sticking together). Clopidogrel stops the platelets aggregating by blocking a substance called ADP from attaching to a special receptor on their surface. This stops the platelets becoming ‘sticky’, reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.

How has Clopidogrel TAD been studied?

Because Clopidogrel TAD is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

What are the benefits and risks of Clopidogrel TAD?

Because Clopidogrel TAD is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine’s.

Why is Clopidogrel TAD approved?

The European Medicines Agency concluded that, in accordance with EU requirements, Clopidogrel TAD has been shown to have comparable quality and to be bioequivalent to Plavix. Therefore, the Agency’s view was that, as for Plavix, the benefit outweighs the identified risk. The Agency recommended that Clopidogrel TAD be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of Clopidogrel TAD?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Clopidogrel TAD have been included in the summary of product characteristics and the package leaflet.

Other information about Clopidogrel TAD

The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel TAD on 23 September 2009.

For more information about treatment with Clopidogrel TAD, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Clopidogrel TAD : EPAR - Summary for the public BG = bălgarski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public ES = español 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public CS = čeština 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public DA = dansk 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public DE = Deutsch 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public ET = eesti keel 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public EL = elliniká 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public EN = English 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public FR = français 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public IT = italiano 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public LV = latviešu valoda 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public LT = lietuvių kalba 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public HU = magyar 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public MT = Malti 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public NL = Nederlands 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public PL = polski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public PT = português 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public RO = română 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public SK = slovenčina 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public SL = slovenščina 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public FI = suomi 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public SV = svenska 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Summary for the public HR = Hrvatski 2009-10-15 2017-09-13

This EPAR was last updated on 13/09/2017 .

Authorisation details

Product details

Product details for Clopidogrel TAD
NameClopidogrel TAD
Agency product numberEMEA/H/C/001136
Active substance

clopidogrel hydrochloride

International non-proprietary name (INN) or common name

clopidogrel

Therapeutic area Peripheral Vascular DiseasesStrokeMyocardial Infarction
Anatomical therapeutic chemical (ATC) code B01AC06
Generic

A generic medicine is a medicine which is similar to a medicine that has already been authorised (the 'reference medicine'). A generic medicine contains the same quantity of active substance(s) as the reference medicine. Generic and reference medicines are used at the same dose to treat the same disease, and they are equally safe and effective.

Publication details

Publication details for Clopidogrel TAD
Marketing-authorisation holder

Tad Pharma GmbH

Revision7
Date of issue of marketing authorisation valid throughout the European Union23/09/2009

Contact address:

TAD Pharma GmbH
Heinz-Lohmann-Strasse 5
D-27472 Cuxhaven
Germany

Product information

Product information

19/07/2017  Clopidogrel TAD -EMEA/H/C/001136 -IB/0028/G

Name Language First published Last updated
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13
Clopidogrel TAD : EPAR - Product Information HR = Hrvatski 2009-10-15 2017-09-13

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16
Clopidogrel TAD : EPAR - All Authorised presentations HR = Hrvatski 2009-10-15 2010-02-16

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:

    Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Clopidogrel TAD : EPAR - Procedural steps taken and scientific information after authorisation HR = Hrvatski 2010-02-16 2017-09-13

Initial marketing-authorisation documents

Name Language First published Last updated
Clopidogrel TAD : EPAR - Public assessment report HR = Hrvatski 2009-10-15  
Committee for medicinal products for human use summary of positive opinion for Clopidogrel TAD HR = Hrvatski 2009-06-25  

Authorised

This medicine is approved for use in the European Union

More information on Clopiogrel TAD